Real-world experience with CPX-351 in high-risk acute myeloid leukemia

被引：6
|
作者：
Lemoli, Roberto M. [1 ,2 ,5 ,6 ]
Montesinos, Pau [3 ]
Jain, Akriti [4 ]
机构：
[1] IRCCS Osped Policlin San Martino, Genoa, Italy
[2] Univ Genoa, Clin Hematol, Genoa, Italy
[3] Hosp Univ & Politecn La Fe, Valencia, Spain
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] IRCCS Osped Policlin San Martino, Clin Hematol, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy
[6] Univ Genoa, Dept Internal Med & Med Specialties, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 185卷
关键词：
AML; Chemotherapy; CPX-351; Cytarabine; Daunorubicin; Real; -world; Measurable residual disease; RESIDUAL DISEASE; AML PATIENTS; SECONDARY; CHEMOTHERAPY; DAUNORUBICIN; AZACITIDINE; VENETOCLAX; CYTARABINE; ADULTS; AGE;
D O I：
10.1016/j.critrevonc.2023.103984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged & GE;1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses realworld studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias J.
    Gborogen, Rosilyn A.
    Chamoun, Kamal
    Wierda, William G.
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [2] Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
    Christina Rautenberg
    Friedrich Stölzel
    Christoph Röllig
    Matthias Stelljes
    Verena Gaidzik
    Michael Lauseker
    Oliver Kriege
    Mareike Verbeek
    Julia Marie Unglaub
    Felicitas Thol
    Stefan W. Krause
    Mathias Hänel
    Charlotte Neuerburg
    Vladan Vucinic
    Christian-Friedrich Jehn
    Julia Severmann
    Maxi Wass
    Lars Fransecky
    Jens Chemnitz
    Udo Holtick
    Kerstin Schäfer-Eckart
    Josephine Schröder
    Sabrina Kraus
    William Krüger
    Ulrich Kaiser
    Sebastian Scholl
    Kathrin Koch
    Lea Henning
    Guido Kobbe
    Rainer Haas
    Nael Alakel
    Maximilian-Alexander Röhnert
    Katja Sockel
    Maher Hanoun
    Uwe Platzbecker
    Tobias A. W. Holderried
    Anke Morgner
    Michael Heuser
    Tim Sauer
    Katharina S. Götze
    Eva Wagner-Drouet
    Konstanze Döhner
    Hartmut Döhner
    Christoph Schliemann
    Johannes Schetelig
    Martin Bornhäuser
    Ulrich Germing
    Thomas Schroeder
    Jan Moritz Middeke
    Blood Cancer Journal, 11
  • [3] Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
    Rautenberg, Christina
    Stoelzel, Friedrich
    Roellig, Christoph
    Stelljes, Matthias
    Gaidzik, Verena
    Lauseker, Michael
    Kriege, Oliver
    Verbeek, Mareike
    Unglaub, Julia Marie
    Thol, Felicitas
    Krause, Stefan W.
    Haenel, Mathias
    Neuerburg, Charlotte
    Vucinic, Vladan
    Jehn, Christian-Friedrich
    Severmann, Julia
    Wass, Maxi
    Fransecky, Lars
    Chemnitz, Jens
    Holtick, Udo
    Schaefer-Eckart, Kerstin
    Schroeder, Josephine
    Kraus, Sabrina
    Krueger, William
    Kaiser, Ulrich
    Scholl, Sebastian
    Koch, Kathrin
    Henning, Lea
    Kobbe, Guido
    Haas, Rainer
    Alakel, Nael
    Roehnert, Maximilian-Alexander
    Sockel, Katja
    Hanoun, Maher
    Platzbecker, Uwe
    Holderried, Tobias A. W.
    Morgner, Anke
    Heuser, Michael
    Sauer, Tim
    Goetze, Katharina S.
    Wagner-Drouet, Eva
    Doehner, Konstanze
    Doehner, Hartmut
    Schliemann, Christoph
    Schetelig, Johannes
    Bornhaeuser, Martin
    Germing, Ulrich
    Schroeder, Thomas
    Middeke, Jan Moritz
    BLOOD CANCER JOURNAL, 2021, 11 (10)
  • [4] Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
    Matthews, Andrew H.
    Perl, Alexander E.
    Luger, Selina M.
    Loren, Alison W.
    Gill, Saar I.
    Porter, David L.
    Babushok, Daria V.
    Maillard, Ivan P.
    Carroll, Martin P.
    Frey, Noelle V.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Stadtmauer, Edward A.
    Paralkar, Vikram R.
    Bruno, Ximena Jordan
    Hwang, Wei -Ting
    Margolis, David
    Pratz, Keith W.
    BLOOD ADVANCES, 2022, 6 (13) : 3997 - 4005
  • [5] Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
    Rautenberg, Christina
    Stoelzel, Friedrich
    Roellig, Christoph
    Stelljes, Matthias
    Gaidzik, Verena
    Lauseker, Michael
    Kriege, Oliver
    Verbee, Mareike
    Unglaub, Julia Marie
    Thol, Felicitas
    Krause, Stefan W.
    Haenel, Mathias
    Neuerburg, Charlotte
    Vucinic, Vladan
    Jehn, Christian-Friedrich
    Severmann, Julia
    Wass, Maxi
    Fransecky, Lars
    Chemnitz, Jens
    Holtick, Udo
    Schaefer-Eckart, Kerstin
    Schroeder, Josephine
    Kraus, Sabrina
    Krueger, William
    Kaiser, Ulrich
    Scholl, Sebastian
    Koch, Kathrin
    Henning, Lea
    Kobbe, Guido
    Haas, Rainer
    Alakel, Nael
    Roehnert, Maximilian-Alexander
    Sockel, Katja
    Hanoun, Maher
    Platzbecker, Uwe
    Holderried, Tobias A. W.
    Morgner, Anke
    Heuser, Michael
    Sauer, Tim
    Goetze, Katharina S.
    Wagner-Drouet, Eva
    Doehne, Konstanze
    Doehner, Hartmut
    Schliemann, Christoph
    Schetelig, Johannes
    Bornhaeuser, Martin
    Germing, Ulrich
    Schroeder, Thomas
    Middeke, Jan Moritz
    BLOOD, 2021, 138
  • [6] Real-World Outcomes with CPX-351 Induction in Adults with Newly Diagnosed Acute Myeloid Leukemia
    Bennett, Joseph G.
    Gilmore, Drake
    Male, Heather J.
    Byrd, Kenneth P.
    Lin, Tara L.
    Gonzalez-Lugo, Jesus D.
    BLOOD, 2023, 142
  • [7] Real-World Study of CPX-351 Treatment Outcomes for Acute Myeloid Leukemia (AML) in England
    Legg, Alex
    Doubleday, Pesheya
    Reich, Adam
    Lambova, Alexandrina
    Medalla, Greg
    BLOOD, 2021, 138
  • [8] Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service
    Legg, Alex
    Lambova, Alexandrina
    Broe, Anne
    Levy, Julia
    Medalla, Greg
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (10): : E323 - E330
  • [9] Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia
    Mitchell, Joshua
    Pfeiffer, Michael
    Boehmer, John
    Gorcsan, John
    Dronamraju, Nalina
    Faderl, Stefan
    Lin, Tara L.
    Uy, Geoffrey L.
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Ghayas C. Issa
    Hagop M. Kantarjian
    Lianchun Xiao
    Jing Ning
    Yesid Alvarado
    Gautam Borthakur
    Naval Daver
    Courtney D. DiNardo
    Elias Jabbour
    Prithviraj Bose
    Nitin Jain
    Tapan M. Kadia
    Kiran Naqvi
    Naveen Pemmaraju
    Koichi Takahashi
    Srdan Verstovsek
    Micheal Andreeff
    Steven M. Kornblau
    Zeev Estrov
    Alessandra Ferrajoli
    Guillermo Garcia-Manero
    Maro Ohanian
    William G. Wierda
    Farhad Ravandi
    Jorge E. Cortes
    Leukemia, 2020, 34 : 2914 - 2924
12345